Healthcare Services

An Important Factor Driving the Tumor Marker Testing Market Is the Rising Cancer Prevalence Driving Growth In Tumor Marker Testing Market

April 7, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Tumor Marker Testing Market Evolve From 2026 To 2030?

The tumor marker testing market has experienced robust expansion in recent years. This market is projected to expand from $18.6 billion in 2025 to $20.12 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.2%. Historically, this expansion has been driven by factors such as a rise in cancer incidence rates, the increased adoption of laboratory diagnostics within oncology, the broadening of hospital-based cancer testing services, the presence of well-established biochemical markers, and the development of diagnostic laboratory networks.

The tumor marker testing market is projected to experience substantial expansion over the upcoming years. This market is set to reach $27.23 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.9%. Factors driving this growth during the projected timeframe include the escalating need for prompt cancer identification, the wider implementation of precision oncology strategies, the broadening scope of companion diagnostics, the increasing application of biomarkers for selecting therapies, and progress in cancer biomarker investigations. Key trends anticipated within this forecast period encompass the greater uptake of multiplex tumor marker panels, the surge in the utilization of blood-based cancer diagnostics, the increasing incorporation of tumor markers into treatment oversight, the expansion of initiatives for early cancer screening, and a heightened emphasis on individualized oncology care.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20668&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Tumor Marker Testing Market?

The rising incidence of cancer is anticipated to fuel the expansion of the tumor marker testing market in the future. Cancer is defined as a condition marked by the uncontrolled multiplication of atypical cells within the body. These malignant cells possess the ability to infiltrate adjacent tissues and disseminate to various bodily regions via the bloodstream and lymphatic systems. The escalation in cancer rates stems from contributors like an aging populace, heightened exposure to environmental factors, shifts in lifestyle, and advancements in detection and diagnostic methods. Tumor marker testing serves the purpose of diagnosing, tracking the effectiveness of treatment, and identifying the re-emergence of different cancers through the measurement of particular substances generated by cancerous cells. As an illustration, the National Health Service, a Uk-based government agency, reported that in October 2025, the year 2023 saw 354,820 new cancer diagnoses, averaging 972 daily, which represented an increase of 8,605 compared to 2022. Consequently, the escalating prevalence of cancer is propelling the growth of the tumor marker testing market.

Which Segment Areas Are Covered In The Tumor Marker Testing Market Analysis?

The tumor marker testing market covered in this report is segmented –

1) By Product: Biochemical Markers, Oncogenes, Growth Factors, Hormones, Colony Stimulating Factors, Lymphokines

2) By Methods: Screening, Imaging, Theranostics, Other Methods

3) By Application: Hospitals, Commercial Or Private Laboratories, Physician Offices Or Group Practices, Cancer Clinics, Ambulatory Care Centers

Subsegments:

1) By Biochemical Markers: Alpha-fetoprotein (AFP), Prostate-Specific Antigen (PSA), Carcinoembryonic Antigen (CEA), Cancer Antigen 125 (CA 125), Cancer Antigen 19-9 (CA 19-9), Human Chorionic Gonadotropin (hCG)

2) By Oncogenes: HER2 Or neu, KRAS, BRAF, EGFR (Epidermal Growth Factor Receptor), c-MYC, p53

3) By Growth Factors: Vascular Endothelial Growth Factor (VEGF), Platelet-Derived Growth Factor (PDGF), Transforming Growth Factor-beta (TGF-ß), Fibroblast Growth Factor (FGF), Insulin-like Growth Factor (IGF)

4) By Hormones: Estrogen Receptors (ER), Progesterone Receptors (PR), Thyroglobulin, Calcitonin, Adrenocorticotropic Hormone (ACTH), Gastrin

5) By Colony Stimulating Factors: Granulocyte Colony-Stimulating Factor (G-CSF), Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), Macrophage Colony-Stimulating Factor (M-CSF)

6) By Lymphokines: Interleukin-2 (IL-2), Interferon-gamma (IFN-?), Tumor Necrosis Factor-alpha (TNF-a), Interleukin-6 (IL-6)

Which Trends Are Shaping The Future Of The Tumor Marker Testing Market?

Leading companies engaged in the tumor marker testing market are intensifying their efforts to develop sophisticated tests, like molecular testing solutions, to achieve a competitive edge. Molecular testing solutions are defined as advanced diagnostic methods that examine genetic material (DNA or RNA) to identify mutations, pathogens, or particular biomarkers at a molecular level. For instance, in April 2024, RGCC International GmbH, a Switzerland-based firm specializing in personalized cancer treatment, launched Onco-D-clare, an innovative cancer detection test. This novel test empowers individuals to detect cancer before symptoms emerge by utilizing a combination of molecular biology and artificial neural networks. Onco-D-clare operates by extracting peripheral blood mononuclear cells from blood samples and then performing an extensive gene expression analysis across more than 90 genes.

Which Global Companies Are Actively Competing In The Tumor Marker Testing Market?

Major companies operating in the tumor marker testing market are Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche AG, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson and Company (BD), Quest Diagnostics Inc., Agilent Technologies Inc, Hologic Inc., Illumina Inc., bioMérieux SA, Bio-Rad Laboratories Inc., Qiagen N.V., DiaSorin S.p.A., Myriad Genetics, Ortho Clinical Diagnostics PLC, Veracyte Inc., Biodesix Inc., Biocept Inc., Proteomedix AG, OncoCyte Corporation, Biocartis NV

Read the full tumor marker testing market report here:

https://www.thebusinessresearchcompany.com/report/tumor-marker-testing-global-market-report

What Are The Leading Geographic Regions In The Tumor Marker Testing Market?

North America was the largest region in the tumor marker testing market in 2025. The regions covered in the tumor marker testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Tumor Marker Testing Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20668&type=smp

Browse Through More Reports Similar to the Global Tumor Marker Testing Market 2026, By The Business Research Company

Circulating Tumor Cells Global Market Report

https://www.thebusinessresearchcompany.com/report/circulating-tumor-cells-global-market-report

Tumor Necrosis Factor Inhibitor Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/tumor-necrosis-factor-inhibitor-drugs-global-market-report

Tumor Infiltrating Lymphocytes Global Market Report

https://www.thebusinessresearchcompany.com/report/tumor-infiltrating-lymphocytes-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795